The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial - Sandhu, S K; Schelman, W R; Wilding, G (Lancet Oncol, 2014)
et al.